进展期胃癌淋巴结清扫研究进展

doi:10.11904/j.issn.1002-3070.2019.01.014

Abstract

Abstract: Standard gastric cancer D2 radical surgery has become a global consensus.However,selective augmentation of lymph node dissection(D2+)surgery for a particular patient may increase their survival.D2 combined with No.8p,No.10,No.12b,No.13,No.14v,No.16a2/b1 lymph node dissection may lead to corresponding surgery-related complications.Therefore,we recommend that patients should be performed appropriate D2+ radical surgery at a medical treatment center with sufficient clinical experience.

Key words: Advanced gastric cancer, No.10, No.12, No.14v, No16a2/b1

CLC Number:

R735.2

ZHANG Bao, ZHENG Zhichao. Research progress in lymph nodes dissection of advanced gastric cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 78-81.

References

1 符涛,季加孚.胃癌诊疗的热点和问题[J].中国肿瘤临床,2016,43(1):2-5.
2 Costamagna G,Cesaro P.Early gastric cancer:detection and endoscopic treatment[J].Ann Ital Chir,2012,83(3):183-191.
3 Basaran H,Koca T,Cerkesli AK,et al.Treatment outcomes and survival study of gastric cancer patients:a retrospective analysis in an endemic region[J].Asian Pac J Cancer Prev,2015,16(5):2055-2060.
4 Galizia G,Lieto E,Auricchio A,et al.Comparison of the current AJCC-TNM numeric-based with a new anatomical location-based lymph node staging system for gastric cancer:A western experience[J].PLoS One,2017,12(4):e0173619.
5 Sano T,Coit DG,Kim HH,et al.Proposal of a new stage grouping of gastric cancer for TNM classification:International Gastric Cancer Association staging project[J].Gastric Cancer,2016,20(2):1-9.
6 Mahul BAMD,Frederick LGMD,Stephen BEMD,et al.The Eighth Edition AJCC Cancer Staging Manual:Continuing to build a bridge from a population‐based to a more "personalized" approach to cancer staging[J].CA Cancer J Clin,2017,67(2):93-99.
7 Association JGC.Japanese gastric cancer treatment guidelines 2010(ver.3)[J].Gastric Cancer,2017,62(2):113-123.
8 Marrelli D,De Franco L,Iudici L,et al.Lymphadenectomy:state of the art[J].Transl Gastroenterol Hepatol,2017,2:3.
9 Tóth D,Plósz J,Török M.Clinical significance of lymphadenectomy in patients with gastric cancer[J].World J Gastrointest Oncol,2016,8(2):136-146.
10 中华人民共和国卫生部医政司.胃癌诊疗规范(2011年版)[J].中国医学前沿杂志(电子版),2012,4(5):62-71.
11 Biondi A,D′Ugo D,Cananzi FC,et al.Does a minimum number of 16 retrieved nodes affect survival in curatively resected gastric cancer?[J].Eur J Surg Oncol,2015,41(6):779-786.
12 陈路川,魏晟宏,叶再生,等.进展期胃癌No.8p淋巴结转移的危险因素及预后分析[J].中华胃肠外科杂志,2017,20(2):218-223.
13 武卫鹏,邓靖宇,梁寒,等.远端胃癌淋巴结转移规律及临床意义[J].中国肿瘤临床,2015,42(18):906-911.
14 Sasada S,Ninomiya M,Nishizaki M,et al.Frequency of lymph node metastasis to the splenic hilus and effect of splenectomy in proximal gastric cancer[J].Anticancer Res,2009,29(8):3347-3351.
15 Zhu G,Sun Z,Wang Z,et al.Splenic hilar lymph node metastasis independently predicts poor survival for patients with gastric cancers in the upper and/or the middle third of the stomach[J].J Surg Oncol,2012,105(8):786-792.
16 Hyung WJ,Lim JS,Song J,et al.Laparoscopic spleen-preserving splenic hilar lymph node dissection during total gastrectomy for gastric cancer[J].J Am Coll Surg,2008,207(2):e6.
17 Hong ZL,Chen QY,Zheng CH,et al.A preoperative scoring system to predict the risk of No.10 lymph node metastasis for advanced upper gastric cancer:a large case report based on a single-center study[J].Oncotarget,2017,8(45):80050-80060.
18 Huang CM,Chen QY,Lin JX,et al.Huang＇s three-step maneuver for laparoscopic spleen-preserving No.10 lymph node dissection for advanced proximal gastric cancer[J].Chin J Cancer Res,2014,26(2):208-210.
19 Feng JF,Huang Y,Liu J,et al.Risk factors for No.12p and No.12b lymph node metastases in advanced gastric cancer in China[J].Ups J Med Sci,2013,118(1):9-15.
20 You X,Wang Y,Li W,et al.Clinical significance of No.12 lymph node dissection for advanced gastric cancer[J].Zhonghua Wei Chang Wai Ke Za Zhi,2017,20(3):283-288.
21 Songun I,Putter H,Kranenbarg EM,et al.Surgical treatment of gastric cancer:15-year follow-up results of the randomised nationwide Dutch D1D2 trial[J].Lancet Oncol,2010,11(5):404-405.
22 Association JGC.Japanese gastric cancer treatment guidelines 2014(ver.4)[J].Gastric Cancer,2017,20(1):1-19.
23 Kumagai K,Sano T,Hiki N,et al.Survival benefit of “D2-plus” gastrectomy in gastric cancer patients with duodenal invasion[J].Gastric Cancer,2017,21(20):1-7.
24 Eom BW,Joo J,Park B,et al.Improved survival after adding dissection of the superior mesenteric vein lymph node(14 v)to standard D2 gastrectomy for advanced distal gastric cancer[J].Surgery,2014,156(3):737-738.
25 陈若华,汪灏,王萌,等.胃癌肠系膜上静脉旁淋巴结转移的影响因素分析[J].中华胃肠外科杂志,2014,17(2):155-157.
26 Sano T,Sasako M,Yamamoto S,et al.Gastric cancer surgery:morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501[J].J Clin Oncol,2004,22(14):2767-2773.
27 Sasako M,Sano T,Yamamoto S,et al.D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer[J].N Engl J Med,2008,359(5):453.
28 Kaito A,Kinoshita T,Tokunaga M,et al.Prognostic factors and recurrence pattern of far-advanced gastric cancer with pathologically-positive para-aortic lymph nodes[J].Anticancer Res,2017,37(7):3685-3692.
29 Zhang Y,Tian S.Does D2 plus para-aortic nodal dissection surgery offer a better survival outcome compared to D2 surgery only for gastric cancer consistently? A definite result based on a hospital population of nearly two decades[J].Scand J Surg,2013,102(4):251-257.
30 Tsuburaya A,Mizusawa J,Tanaka Y,et al.Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis[J].Br J Surg,2014,101(6):653-660.
31 Wang Y,Yu YY,Li W,et al.A phase II trial of Xeloda and oxaliplatin(XELOX)neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis[J].Cancer Chemother Pharmacol,2014,73(6):1155-1161.
32 梁月祥,梁寒,丁学伟,等.N3期胃癌D2联合腹主动脉旁淋巴结清扫对患者生存预后的影响[J].中华外科杂志,2013,51(12):1071-1076.
33 梁寒.局部进展期胃癌的精准淋巴结清扫[J].中华胃肠外科杂志,2016,19(2):138-143.

[1]	ZHANG Xi ,CHEN Li ,XUE Yingwei. Prognostic value of CEA and CA19-9 expression in peripheral blood of patients with advanced gastric cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 342-347.
[2]	DONG Feng,MA Junjun,CAI Zhenghao,ZHAO Xuan,ZHENG Minhua. The correlation between serum miR-21 and miR-34a expression and the efficacy of Flofox chemotherapy regimen in patients with advanced gastric carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 147-151.
[3]	DING Yuan,CHEN Yuqiang,LI Yue,MI Yanjun,YE Yanhua,LI Qiang. Clinical controlled trial of the advanced gastric patients with ascites by intra-abdominal infusion of DC-CIK or rmhTNF [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(1): 12-16.
[4]	LIANG Yongjun,JING Xiaohui,LIU Yugang,GUO Yunjie,YANG Lili,WANG Fen. Clinical study of FOLFOX6 regimen in the treatment of advanced gastric cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(6): 537-539.
[5]	XU Yaye,CHEN Xuefa,LI Xiujuan,ZHOU Zhenshou. Spiral CT scanning in the advanced stage of invasion depth of gastric cancer research [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(2): 146-149.
[6]	LIU Lei, GU Manling. Clinical comparison of docetaxel/capecitabine and oxaliplatin/capecitabine in treating advanced gastric cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2010, 24(1): 62-63.

Research progress in lymph nodes dissection of advanced gastric cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 6

Recommended Articles

Metrics

Comments